Reaction
Joint Ankylosis reporting signals
As of the last recalculation, Joint Ankylosis appears in 566 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is DESOXIMETASONE (PRR 166.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Desoximetasone | 75 | 166.7 | 167.4 |
| Sulfasalazine | 104 | 59.7 | 59.7 |
| Tofacitinib Citrate | 18 | 52.1 | 52.2 |
| Tranexamic Acid | 11 | 46.4 | 46.4 |
| Canagliflozin | 33 | 43.0 | 43.1 |
| Leflunomide | 91 | 37.9 | 37.9 |
| Tocilizumab | 92 | 35.2 | 35.2 |
| Hydroxychloroquine | 57 | 31.1 | 31.1 |
| Golimumab | 60 | 28.7 | 28.7 |
| Canakinumab | 8 | 27.6 | 27.6 |
| Secukinumab | 99 | 27.1 | 27.1 |
| Lapatinib | 11 | 26.6 | 26.6 |
| Ustekinumab | 53 | 20.9 | 20.9 |
| Carfilzomib | 15 | 20.0 | 20.0 |
| Ixazomib | 12 | 15.6 | 15.7 |
| Certolizumab Pegol | 43 | 14.5 | 14.5 |
| Daratumumab | 15 | 14.2 | 14.2 |
| Palivizumab | 5 | 12.1 | 12.1 |
| Apremilast | 36 | 9.6 | 9.6 |